Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2022 Feb 10;15:806713. doi: 10.3389/fnins.2021.806713

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Copyright © 2022 Khan, Nazir, Farooq, Khan and Javed.

This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

PMC Copyright notice

Proposed mechanism of diosgenin encapsulated SLNPs and diosgenin only activity on Con-A–induced sickness in animal model and in vitro analysis. (A) Con-A induces sickness in animal model due to its ability of triggering immune system, which results in the production of inflammatory cytokines. Diosgenin when in carrier decreases the inflammation and its capability of crossing the BBB boosts up while being least toxic. This formulation also restored the normal behavior in sickness mice model and showed anti-proliferative activity in cell line by the regulation of apoptotic molecules. (B) Diosgenin only still shows its therapeutic capability, but being steroid in nature, it is not soluble and its capability to cross the BBB is low. It gets highly concentrated in spleen and liver, which is the site of inflammatory responses.